Rubraca (rucaparib) / Clovis  >>  Phase 2
Welcome,         Profile    Billing    Logout  

32 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rubraca (rucaparib) / Pharma& Schweiz
2014-003319-12: Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)

Ongoing
2
91
Europe
Rucaparib (camphorsulfonic acid salt form), CO-338, Tablet
The Royal Marsden NHS Foundation Trust, The Insitute of Cancer Research, Clovis Oncology Inc., Cancer Research UK - Endorsement,
Primary breast cancer, Primary breast cancer, Diseases [C] - Cancer [C04]
 
 
2015-003249-25: ATLANTIS: An adaptive multi-arm phase II trial of maintenance targeted therapy after chemotherapy in metastatic urothelial cancer

Ongoing
2
268
Europe
Cabozantinib, Rucaparib, Enzalutamide, XL184, Tablet, Capsule, soft, Cometriq, Enzalutamide
NHS Greater Glasgow & Clyde, University of Glasgow, Cancer Research UK, Exelixis Inc, Clovis Oncology Inc, Astellas Pharma Europe,
Metastatic urothelial cancer, Cancer of the bladder or associated structures which has spread to other parts of the body., Diseases [C] - Cancer [C04]
 
 
2017-002860-42: A randomized phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer preceded by a phase I dose escalation study on Rucaparib-Bevacizumab combination . Studio randomizzato di fase II con Carboplatino-Paclitaxel-Bevacizumab vs Carboplatino-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatino-Paclitaxel-Rucaparib in pazienti con tumore ovarico avanzato (stadio IIIB-C-IV), primitivo del peritoneo e della tuba di Falloppio, preceduto da uno studio di Fase I, di identificazione della dose, con Rucaparib in combinazione con Bevacizumab.

Not yet recruiting
2
234
Europe
Rucaparib, Avastin, Paclitaxel, Carboplatino, [CO-338], [Ro 487-6646], [Bevacizumab], [Paclitaxel], [NA], Tablet, Concentrate for solution for infusion, Solution for infusion, Rubraca, AVASTIN - 1 FLACONCINO DA 100 MG DI CONCENTRATO PER SOLUZIONE PER INFUSIONE, AVASTIN - 1 FLACONCINO DA 400 MG DI CONCENTRATO PER SOLUZIONE PER INFUSIONE, PACLITAXEL MYLAN GENERICS - 6 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO DI VETRO DA 5 ML, CARBOPLATINO AHCL - 10 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO DI VETRO DA 5 ML
FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE, CLOVIS ONCOLOGY, INC
Advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer. Tumore ovarico avanzato (stadio IIIB-C-IV), primitivo del peritoneo e della tuba di Falloppio., Advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer. Tumore ovarico avanzato (stadio IIIB-C-IV), primitivo del peritoneo e della tuba di Falloppio., Diseases [C] - Cancer [C04]
 
 
2017-001626-17: An Investigational Immunotherapy Study to Determine Which Combination of Nivolumab plus Several Other Drugs, is the Most Effective in Treating Castration-resistant Prostate Cancer That Has Spread Un estudio de inmunoterapia en investigación para determinar qué combinación de Nivolumab con otros medicamentos es la más eficaz en el tratamiento del cáncer de próstata resistente a la castración

Ongoing
2
300
Europe
NIVOLUMAB, Rucaparib, DOCETAXEL, Enzalutamide, BMS-936558, Concentrate for solution for infusion, Film-coated tablet, Capsule, soft, Opdivo (100 mg/10 ml), Docetaxel Hospira 10 mg/ml Concentrate for Solution for Infusion, Doce NC 10 mg/ml Concentrate for Solution for Infusion, Xtandi 40 mg soft capsules
Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb International Corporation
Castration-resistant Metastatic Prostate Cancer Cáncer de próstata metastásico resistente a la castración, Castration-resistant Prostate Cancer That Has Spread Cáncer de próstata resistente a la castración que se ha diseminado, Diseases [C] - Cancer [C04]
 
 
2017-003353-41: Mesothelioma Stratified Therapy (MiST) - Including the following treatment arms: MiST 1 rucaparibMiST 2 abemaciclibMiST 3 pembrolizumab in combination with bemcentinibMiST 4 atezolizumab in combination with bevacizumabMiST 5 dostarlimab in combination with niraparib

Not yet recruiting
2
120
Europe
rucaparib, abemaciclib, Tecentriq, Avastin (for the 100mg/4ml presentation), Avastin (for 400 mg/16 ml presentation), Pembrolizumab, bemcentinib, KEYTRUDA (Pembrolizumab, MK3475), KEYTRUDA (pembrolizumab, MK3475), Niraparib, Dostarlimab, CO-338, LY2835219, R05541267/F03, RO4876646/F01, RO4876646/F02, MK-3475, BGB324, Tablet, Capsule, hard, Concentrate for solution for infusion, Solution for infusion, Capsule, Tecentriq, Avastin (for the 100mg/4ml presentation), Avastin (for 400 mg/16 ml presentation), KEYTRUDA (Pembrolizumab, MK3475), KEYTRUDA (pembrolizumab, MK3475), Niraparib
University of Leicester, The British Lung Foundation, Clovis Pharmaceuticals Inc., Eli Lilly & Company, Roche Pharma AG, Merck Sharp & Dohme Limited, BerGenBio ASA, GlaxoSmithKline Research & Development Limited
Malignant Mesothelioma (MM) - pleural and peritoneal, Mesothelioma is a universally lethal cancer caused by Asbestos. There has only been one licenced therapy since 2003. Accordingly there is a pressing need for effective therapy in the relapsed setting, Diseases [C] - Cancer [C04]
 
 
2017-004780-13: Trial to investigate whether the addition of nivolumab or nivolumab and ipilimuab to rucaparib improves effectiveness, compared with rucaparib alone, in patients with relapsed ovarian cancer.

Ongoing
2
252
Europe
rucaparib, nivolumab, ipilimumab, Tablet, Concentrate for solution for infusion, nivolumab, ipilimumab
NHS Greater Glasgow & Clyde, University of Glasgow
High grade serous ovarian cancer (includes histologically identical fallopian tube and primary peritoneal cancers and high grade G3 endometrioid histological subtypes), Ovarian cancer, Diseases [C] - Cancer [C04]
 
 
Clovis-001, NCT03476798: Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium

Completed
2
49
US
Rucaparib, Bevacizumab
University of Oklahoma, Clovis Oncology, Inc.
Cervical Cancer, Endometrial Cancer
05/20
09/23
NCT03140670: Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

Terminated
2
46
US
RUCAPARIB
Abramson Cancer Center at Penn Medicine
Pancreatic Cancer
10/20
08/23
CheckMate 9KD, NCT03338790: An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Checkmark Final data from cohort A2 of CheckMate 9KD trial in combination with Rubraca for mCRPC at ESMO 2021
Sep 2021 - Sep 2021: Final data from cohort A2 of CheckMate 9KD trial in combination with Rubraca for mCRPC at ESMO 2021
Checkmark For metastatic castration resistant prostate cancer (CheckMate 9KD trial)
Sep 2019 - Sep 2019: For metastatic castration resistant prostate cancer (CheckMate 9KD trial)
Active, not recruiting
2
292
Europe, Canada, US, RoW
nivolumab, BMS-936558, Opdivo, docetaxel, enzalutamide, rucaparib, prednisone
Bristol-Myers Squibb, Clovis Oncology, Inc., Astellas Pharma Inc
Prostate Cancer
01/21
09/24
2018-004207-39: Mirvetuximab Soravtansine in patients with high expression of folate receptor alpha in their tumor and recurrent ovarian cancer

Not yet recruiting
2
136
Europe
Mirvetuximab Soravtansine, Powder and solvent for concentrate for solution for infusion, Solution for infusion, Capsule, hard, Film-coated tablet, , Caelyx, Carboplatin Kabi, Paclitaxel-GRY®, Gemedac®, Zejula, Lynparza, Rubraca
AGO Research GmbH, ImmunoGen, Inc.
This trial evaluates the efficacy and safety of Mirvetuximab soravtansine (IMGN853) plus Carboplatin chemotherapy in FRα high patients with recurrent ovarian cancer who are eligible for platinum-based chemotherapy., Safety and efficacy for carboplatin with Mirvetuximab soravtansine (IMGN853) compared to carboplatin combination chemotherapy, Diseases [C] - Cancer [C04]
 
 
LUNG-MAP Sub-Study, NCT03845296: Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Active, not recruiting
2
64
US
Rucaparib, 6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-, 8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one
SWOG Cancer Research Network, National Cancer Institute (NCI)
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma, Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
01/22
07/24
FRACTION-GC, NCT02935634 / 2016-002807-24: A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

Completed
2
190
Europe, Canada, US, RoW
Nivolumab, Opdivo, BMS-936558, Ipilimumab, Yervoy, BMS-734016, Relatlimab, BMS-986016, BMS-986205, Rucaparib, Rubraca
Bristol-Myers Squibb, Clovis Oncology, Inc.
Advanced Gastric Cancer
05/22
05/22
ROAR, NCT03533946: Rucaparib in Nonmetastatic prOstAte With BRCAness

Terminated
2
7
US
Rucaparib, Rubraca
University of Utah, Clovis Oncology, Inc.
Prostate Cancer
01/23
01/23
NCT03958045: Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma

Active, not recruiting
2
33
US
Rucaparib and Nivolumab
Zhonglin Hao, Clovis Oncology, Inc.
Small Cell Lung Cancer
11/22
07/24
NCT03639935: Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy

Active, not recruiting
2
32
US
Rucaparib, Nivolumab
University of Michigan Rogel Cancer Center, Dana-Farber Cancer Institute, Vanderbilt University Medical Center
Biliary Tract Cancer
02/23
02/25
NCT02873962: A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Active, not recruiting
2
73
US
Bevacizumab, Avastin, Nivolumab, Opdivo, Rucaparib, Rubraca
Dana-Farber Cancer Institute, Bristol-Myers Squibb, Clovis Oncology, Inc.
Peritoneal Cancer, Ovarian Cancer, Fallopian Tube Cancer
07/24
07/26
EndoBARR, NCT03694262: The Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)

Completed
2
30
US
Rucaparib, Rubraca, Bevacizumab, Avastin, Atezolizumab, Tecentriq
Medical College of Wisconsin, Genentech, Inc., Clovis Oncology, Inc.
Endometrial Cancer, Uterine Carcinosarcoma
03/23
04/23
MiST, NCT03654833: Mesothelioma Stratified Therapy () : A Multi-drug Phase II Trial in Malignant Mesothelioma

Active, not recruiting
2
186
Europe
Rucaparib, CO-338, Abemaciclib, LY2835219, pembrolizumab & bemcentinib, Keytruda; BGB324, Atezolizumab & Bevacizumab, MPDL3280A; Avastin, Dostarlimab and Niraparib, Zejula
University of Leicester, British Lung Foundation, Clovis Oncology, Inc., Eli Lilly and Company, Merck Sharp & Dohme LLC, BerGenBio ASA, Roche Pharma AG, University Hospitals, Leicester, The Christie NHS Foundation Trust, GlaxoSmithKline
Mesothelioma, Malignant
10/23
10/23
NCT03617679: Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

Active, not recruiting
2
79
US
Rucaparib, Placebo Oral Tablet
University of Colorado, Denver, Clovis Oncology, Inc., National Cancer Institute (NCI)
Metastatic Endometrial Cancer
10/23
09/24
TRIUMPH, NCT03413995: Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations

Active, not recruiting
2
30
US
Rucaparib
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Clovis Oncology, Inc.
Prostate Cancer Metastatic
11/23
09/24
NCT04624178: A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma

Active, not recruiting
2
20
US
Rucaparib, Nivolumab
Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb, Clovis Oncology, Inc.
Leiomyosarcoma
11/24
11/24
PLATFORM, NCT02678182: Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial

Recruiting
2
924
Europe
Capecitabine, MEDI4736, Trastuzumab, Rucaparib, Ramucirumab
Royal Marsden NHS Foundation Trust, MedImmune LLC, Clovis Oncology, Inc., Eli Lilly and Company, AstraZeneca
Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Gastro-oesophageal Junction, Adenocarcinoma of the Stomach
03/25
06/27
PLATIPARP, NCT03442556: Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

Active, not recruiting
2
18
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Laboratory Biomarker Analysis, Rucaparib Camsylate, 8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic Acid Salt, C0-338, Rubraca, Rucaparib Phosphate, Rucaparib, 283173-50-2, 6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-
University of Washington
ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Homologous Recombination Deficiency, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal to Two, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
05/25
05/25
CA209-8TT, NCT03899155 / 2018-004362-34: Pan Tumor Rollover Study

Recruiting
2
1500
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558-01, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, BMS-986016-01, Nivolumab + Relatlimab, BMS-986213, Capecitabine, Bevacizumab, Temozolomide, Rucaparib, Daratumumab, Regorafinib, Leucovorin, Fluorouracil, Oxaliplatin, Enzalutamide, Sunitinib, Pemetrexed, Pembrolizumab
Bristol-Myers Squibb, Exelixis, Novartis, Clovis Oncology, Inc., Janssen Pharmaceuticals
Cancer
08/29
08/29
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
NCT03337087: Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Active, not recruiting
1/2
18
US
Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Irinotecan Sucrosofate, Irinotecan Liposome, MM-398, nal-IRI, Nanoliposomal Irinotecan, Nanoparticle Liposome Formulation of Irinotecan, Onivyde, PEP02, Laboratory Biomarker Analysis, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Rucaparib, 6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-, 8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
03/21
08/25
NCT04209595: PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers

Active, not recruiting
1/2
10
US
PLX038, PEGylated SN38, Rucaparib, Rubraca, Ondansetron, Zofran
National Cancer Institute (NCI)
Small Cell Lung Cancer, Extra-Pulmonary Small Cell Carcinomas
08/21
12/24
RiME, NCT03995017: Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma

Active, not recruiting
1/2
34
US
Rucaparib, Rubraca, Ramucirumab, Cyramza, Nivolumab, Opdivo, Bristol- Meyers Squibb (BMS)-936558
University of Kansas Medical Center, Bristol-Myers Squibb, Clovis Oncology, Inc.
Esophagus Cancer, Adenocarcinoma, Stomach Cancer, Adenocarcinoma
10/22
12/24
REVOCAN, NCT04826198: Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months

Recruiting
1/2
26
Europe
AsiDNA, Niraparib, Olaparib, Rucaparib
Gustave Roussy, Cancer Campus, Grand Paris
Ovarian Cancer
10/23
10/23
BrUOG 360, NCT04253262: A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

Active, not recruiting
1/2
13
US
Rucaparib, Rubraca, Copanlisib, Aliqopa
Brown University, Rhode Island Hospital, The Miriam Hospital, Bayer, Clovis Oncology, Inc.
Metastatic Castration-resistant Prostate Cancer
01/27
01/27
NCT03559049: Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

Active, not recruiting
1/2
25
US
Pembrolizumab, Pemetrexed, Carboplatin, Rucaparib
University of Michigan Rogel Cancer Center, Merck Sharp & Dohme LLC, Clovis Oncology, Inc.
Stage IV Non-small Cell Lung Cancer
07/24
07/27
MITO25, NCT03462212: Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination

Recruiting
1/2
290
Europe
Carboplatin, Paclitaxel, Bevacizumab, Rucaparib
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Istituto Di Ricerche Farmacologiche Mario Negri, Foundation Medicine
Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer
03/25
03/25

Download Options